medtronic's ceo stands by the research. >>> johnson & johnson is recalling 60,000 bottles of tylenolxtra strength caplets for a musty, moldy odor. >>> our sister network cnbc has named virginia america's top state for business. >>> finally, parents flying on malaysia airlines may need a sitter. the carrier has reportedly banned babies from first class cabins. >>> coming up, the mets slam the tigers. lee shuts down the sox, and america's world cup women in action. plus the orioles luke scott commits home run robbery against the cardinals. your early morning headlines are straight ahead. >>> the fourth of july holiday weekend slowly approaches and right on cue the heat is going to get worse. the forecast is coming up. you're watching "early today." >>> good morning. if you are just waking up, this is "early today." in sports last night the opening game of a matchup many call a potential world series preview was no contest. here's nbc's fred roggin with all your early morning sports headline psp. >> if you don't know by now, the phillies cliff lee is good. he's real good. he was up to h

the drug is called infuse, and it is made by the medtronic corporation. according to the curremedtronic corporation. according to the current issue of the journal "spine surgery," the doctors writing the papers got payments from medtronic as high as $23.5 million and as little as a half million dollars. infuse is used during some spine surgery to make bone growth. side effects include male sterility, pain and death. a doctor at the university of wisconsin said that much of that money came from medtronic for patents on devices he developed, but it did not influence the papers he wrote or edits. other doctors say the same. medtronic says it told the fda about the side effects and warned them on the label. the doctors writing about this say it reveals how much money can be paid to doctors who write about certain drugs and devices. natalie? >> we'll be hearing much more on this story on "nightly news." >>> johnson & johnson is recalling more than 60,000 bottles of tylenol extra-strength caplets due to a moldy odor. the smell is caused by trace amounts of a ch

so with regards to the deo system i will say medtronic and fda has been continually working together and and i believe the ongoing study right now provide sufficient safety data within the u.s. and it is the hope of the fda that the safety data will allow the transition to an outpatient and finally approval of that device. >> thank you. dr. rodgers, last year congress passed legislation extending the funding for the special diabetes program through september of 2013. how important is it for congress to do multiple years as opposed to year-to-year renewals of funding? does that have an impact on the kinds of studies that you can fund? >> senator we were very pleased to see the multiyear renewal of special diabetes program grass through fiscal year 2013. the multiyear renewal greatly improves the planning process that goes on at idd k.. for example many clinical studies take multiple years to perform and it would be very difficult if not impossible to start such a multiyear clinical trial without knowledge of whether the funds will exist in future years to continue those types of funds

so with regards to the deo system i will say medtronic and fda has been continually working together and and i believe the ongoing study right now provide sufficient safety data within the u.s. and it is the hope of the fda that the safety data will allow the transition to an outpatient and finally approval of that device. >> thank you. dr. rodgers, last year congress passed legislation extending the funding for the special diabetes program through september of 2013. how important is it for congress to do multiple years as opposed to year-to-year renewals of funding? does that have an impact on the kinds of studies that you can fund? >> senator we were very pleased to see the multiyear renewal of special diabetes program grass through fiscal year 2013. the multiyear renewal greatly improves the planning process that goes on at idd k.. for example many clinical studies take multiple years to perform and it would be very difficult if not impossible to start such a multiyear clinical trial without knowledge of whether the funds will exist in future years to continue those types of funds

so with regards to the deo system i will say medtronic and fda has been continually working together and and i believe the ongoing study right now provide sufficient safety data within the u.s. and it is the hope of the fda that the safety data will allow the transition to an outpatient and finally approval of that device. >> thank you. dr. rodgers, last year congress passed legislation extending the funding for the special diabetes program through september of 2013. how important is it for congress to do multiple years as opposed to year-to-year renewals of funding? does that have an impact on the kinds of studies that you can fund? >> senator we were very pleased to see the multiyear renewal of special diabetes program grass through fiscal year 2013. the multiyear renewal greatly improves the planning process that goes on at idd k.. for example many clinical studies take multiple years to perform and it would be very difficult if not impossible to start such a multiyear clinical trial without knowledge of whether the funds will exist in future years to continue those types of funds